| Literature DB >> 34845414 |
Abstract
BACKGROUND: Liver inflammation indices reflect its inflammatory microenvironment, which may play a role in the proliferation, invasion, and migration of carcinoma. This study is aimed at exploring the prognostic significance of serum lactate dehydrogenase (LDH) levels and gamma-glutamyl transferase (GGT)/alanine aminotransferase (ALT) ratio in hepatocellular carcinoma after liver transplant (LT).Entities:
Mesh:
Substances:
Year: 2021 PMID: 34845414 PMCID: PMC8627343 DOI: 10.1155/2021/9809990
Source DB: PubMed Journal: Comput Math Methods Med ISSN: 1748-670X Impact factor: 2.238
Clinical characteristics of patients.
| Characteristics | Median (25th-75th percentile) or no. (%) |
|---|---|
| Sex | |
| Male | 142 (91.6) |
| Female | 13 (8.3) |
| Age (years) | 50 (42-58) |
| Child-Pugh class | |
| A | 47 (30.3) |
| B | 87 (56.1) |
| C | 21 (13.5) |
| MELD score | 11 (8-18) |
| Tumor number | |
| <3 | 82 (52.9) |
| ≥3 | 73 (47.1) |
| Largest tumor size (mm) | 44 (25-80) |
| Edmondson grading | |
| I-II | 111 (71.6) |
| III-IV | 44 (28.4) |
| AFP (ng/ml) | 117.24 (10.12-2614.33) |
| BMI (kg/m2) | 22.15 (20.42-24.09) |
| Macrovascular invasion | |
| Yes | 121 (78.1) |
| No | 34 (21.9) |
| Microvascular invasion | |
| Yes | 115 (74.2) |
| No | 40 (25.8) |
| Pre-LT treatment | |
| Surgical resection | 30 (19.3) |
| TACE | 174 (47.7) |
| RFA | 29 (18.7) |
| Milan criteria | |
| Yes | 49 (31.6) |
| No | 106 (68.4) |
| Hangzhou criteria | |
| Yes | 110 (71.0) |
| No | 45 (29.0) |
| HCC recurrence | 65 (41.9) |
| Follow-up (months) | 40 (22-54) |
| GGT (U/l) | 111 (51-201) |
| ALT (U/l) | 38 (25-58) |
| LDH (U/l) | 208 (181-268) |
Figure 1Receiver operating characteristic curves for serum LDH levels (a) and the GGT/ALT ratio (b) in patients with hepatocellular carcinoma after a liver transplant. LDH: lactate dehydrogenase; GGT: gamma-glutamyl transferase; ALT: alanine aminotransferase.
Comparisons of the Areas Under the Curve (AUC) values and the determination of the cut-off values.
| AUC | Cut-off | SE | 95% CI |
| |
|---|---|---|---|---|---|
| LDH | 0.647 | 213.5 | 0.045 | 0.559-0.735 | 0.002 |
| GGT/ALT | 0.704 | 3.1338 | 0.042 | 0.621-0.787 | 0.000 |
Relationship between LDH and GGT/ALT with clinicopathologic parameters.
| Patient-related factors | LDH (U/l) |
| GGT/ALT |
| ||
|---|---|---|---|---|---|---|
| <213.5 | ≥213.5 | <3.1338 | ≥3.1338 | |||
|
|
|
|
| |||
| Sex | 0.546 | 0.276 | ||||
| Male | 75 | 67 | 76 | 66 | ||
| Female | 8 | 5 | 9 | 4 | ||
| Age (years) | 0.430 | 0.159 | ||||
| <60 | 65 | 60 | 72 | 53 | ||
| ≥60 | 18 | 12 | 13 | 17 | ||
| Child-Pugh class | 0.037 | 0.754 | ||||
| A | 27 | 20 | 24 | 23 | ||
| B | 40 | 47 | 50 | 37 | ||
| C | 16 | 5 | 11 | 10 | ||
| Pre-LT treatment | 0.458 | 0.719 | ||||
| Yes | 51 | 40 | 51 | 40 | ||
| No | 32 | 32 | 34 | 30 | ||
| AFP (ng/ml) | 0.062 | 0.000 | ||||
| <400 | 56 | 38 | 63 | 31 | ||
| ≥400 | 27 | 34 | 22 | 39 | ||
| Largest tumor size (mm) | 0.017 | 0.000 | ||||
| <50 | 56 | 35 | 63 | 28 | ||
| ≥50 | 27 | 37 | 22 | 42 | ||
| Tumor number | 0.009 | 0.051 | ||||
| <3 | 52 | 30 | 51 | 31 | ||
| ≥3 | 31 | 42 | 34 | 39 | ||
| Edmondson grading | 0.841 | 0.028 | ||||
| I-II | 60 | 51 | 67 | 44 | ||
| III-IV | 23 | 21 | 18 | 26 | ||
| Macro-vascular invasion | 0.936 | 0.521 | ||||
| Yes | 18 | 16 | 17 | 17 | ||
| No | 65 | 56 | 68 | 53 | ||
| Micro-vascular invasion | 0.006 | 0.001 | ||||
| Yes | 14 | 26 | 13 | 27 | ||
| No | 69 | 46 | 72 | 43 | ||
| Milan criteria | 0.001 | 0.002 | ||||
| Yes | 36 | 13 | 36 | 13 | ||
| No | 47 | 59 | 49 | 57 | ||
| Hangzhou criteria | 0.973 | 0.018 | ||||
| Yes | 59 | 51 | 67 | 43 | ||
| No | 24 | 21 | 18 | 27 | ||
Figure 2Relationship between LDH levels (a, b) and the GGT/ALT ratio (c, d), and overall survival without recurrence. LDH: lactate dehydrogenase; GGT: gamma-glutamyl transferase; ALT: alanine aminotransferase.
Univariate and multivariate analyses of factors for prediction of recurrence-free survival.
| Characteristics | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI |
| HR | 95% CI |
| |
| Sex (male/female) | 1.224 | 0.491-3.051 | 0.664 | |||
| Age (<60/≥60) (years) | 0.904 | 0.483-1.693 | 0.753 | |||
| Child-Pugh stage (A/B/C) | 1.118 | 0.757-1.652 | 0.574 | |||
| MELD score | 1.017 | 0.993-1.041 | 0.179 | |||
| BMI (kg/m2) | 0.970 | 0.896-1.051 | 0.459 | |||
| Tumor number (<3/≥3) | 1.437 | 0.882-2.341 | 0.146 | |||
| Largest tumor size (<50/≥50) (mm) | 2.795 | 1.701-4.593 | 0.000 | 1.841 | 1.096-3.091 | 0.021 |
| Edmondson grading (I-II/III-IV) | 1.805 | 1.081-3.015 | 0.024 | 0.279 | ||
| Pre-LT treatment (yes/no) | 1.077 | 0.653-1.776 | 0.770 | |||
| AFP (<400/≥400) (ng/ml) | 3.320 | 2.017-5.466 | 0.000 | 2.120 | 1.260-3.568 | 0.005 |
| Macrovascular invasion (yes/no) | 1.639 | 0.929-2.892 | 0.088 | |||
| Microvascular invasion (yes/no) | 2.863 | 1.729-4.742 | 0.000 | 1.771 | 1.043-3.010 | 0.035 |
| GGT/ALT (<3.1338/≥3.1338) | 3.361 | 1.998-5.654 | 0.000 | 2.008 | 1.208-3.609 | 0.008 |
| LDH (<213.5/≥213.5) (U/l) | 2.408 | 1.459-3.974 | 0.001 | 1.791 | 1.075-2.985 | 0.025 |